Andrew Berens
Stock Analyst at Leerink Partners
(1.36)
# 3,212
Out of 4,789 analysts
122
Total ratings
45.92%
Success rate
-10.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $26.97 | +107.64% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $9.15 | +216.94% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $85.98 | +12.82% | 24 | May 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $5.73 | +249.34% | 4 | Jan 5, 2023 | |
| ARVN Arvinas | Maintains: Outperform | $74 → $70 | $6.95 | +907.92% | 5 | Nov 23, 2022 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $72.66 | +8.73% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.32 | +241.76% | 3 | May 13, 2022 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $9 → $11 | $2.13 | +416.43% | 2 | May 5, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $5.60 | +614.29% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $1.46 | +4,504.81% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $1 | $0.25 | +307.66% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $4.24 | +678.30% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $11.65 | +114.68% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $111.19 | -13.66% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $69 → $110 | $68.20 | +61.29% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $60.59 | +28.73% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $39.93 | +20.21% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $10.48 | +167.18% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.43 | +1,788.11% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $1.06 | +2,729.12% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.37 | +358.19% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.28 | +1,860.78% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $6.68 | +19.85% | 7 | Jul 14, 2017 |
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $26.97
Upside: +107.64%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $9.15
Upside: +216.94%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $85.98
Upside: +12.82%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $5.73
Upside: +249.34%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $6.95
Upside: +907.92%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $72.66
Upside: +8.73%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.32
Upside: +241.76%
Compass Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $9 → $11
Current: $2.13
Upside: +416.43%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.60
Upside: +614.29%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.46
Upside: +4,504.81%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.25
Upside: +307.66%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $4.24
Upside: +678.30%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $11.65
Upside: +114.68%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $111.19
Upside: -13.66%
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $68.20
Upside: +61.29%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $60.59
Upside: +28.73%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $39.93
Upside: +20.21%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $10.48
Upside: +167.18%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.43
Upside: +1,788.11%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $1.06
Upside: +2,729.12%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.37
Upside: +358.19%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $1.28
Upside: +1,860.78%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $6.68
Upside: +19.85%